Publication | Closed Access

Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer

UrologyGenitourinary CancerMedicineImmune Checkpoint InhibitorAdvanced Urothelial CancerCancer TreatmentSecond-line Anti–pd-1/pd-l1OncologyRadiation OncologyClinical OutcomeMolecular Oncology